Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Eli Lilly and Company. A complete text table follows the diagram.
Mounjaro and Zepbound supplied $12.8B of a $19.8B quarter and funded a rapidly expanding research pipeline
Swipe to explore
Mounjaro and Zepbound values are directly reported; all-other medicines is the exact residual required to reconcile to reported revenue.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Mounjaro | 1 | $8.7B | Diabetes; up 125% year over year |
| Zepbound | 1 | $4.2B | Obesity; up 80% year over year |
| Other medicines & collaboration revenue | 1 | $7.0B | Oncology, immunology, neuroscience and other |
| Revenue | 2 | $19.8B | Up 56% year over year |
| Gross profit | 3 | $16.2B | 81.9% gross margin |
| Cost of sales | 3 | $3.6B | Manufacturing, royalties and distribution |
| Income before tax | 4 | $8.8B | 44.7% of revenue |
| Research & development | 4 | $3.5B | Early and late-stage portfolio; up 28% |
| Marketing, selling & administration | 4 | $2.9B | Launch and commercial investment |
| Acquired in-process R&D | 4 | $584M | Pipeline acquisitions |
| Special charges & other | 4 | $344M | Impairment, restructuring and other net expense |
| Net income | 5 | $7.4B | 37.4% net margin |
| Income tax | 5 | $1.5B | 16.4% effective rate |
| From | To | Value |
|---|---|---|
| Mounjaro | Revenue | $8.7B |
| Zepbound | Revenue | $4.2B |
| Other medicines & collaboration revenue | Revenue | $7.0B |
| Revenue | Gross profit | $16.2B |
| Revenue | Cost of sales | $3.6B |
| Gross profit | Income before tax | $8.8B |
| Gross profit | Research & development | $3.5B |
| Gross profit | Marketing, selling & administration | $2.9B |
| Gross profit | Acquired in-process R&D | $584M |
| Gross profit | Special charges & other | $344M |
| Income before tax | Net income | $7.4B |
| Income before tax | Income tax | $1.5B |